Paul G. Corn, MD, PhD

Peer-Reviewed Articles

1. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. e-Pub 2020. PMID: 32675015.
2. Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clin Cancer Res 26(15):4143-4153, 2020. e-Pub 2020. PMID: 32341031.
3. Labanca E, Vazquez ES, Corn PG, Roberts JM, Wang F, Logothetis CJ, Navone NM. Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer 27(7):R255-R265, 2020. PMID: 32369771.
4. Ramesh N, Sei E, Tsai PC, Bai S, Zhao Y, Troncoso P, Corn PG, Logothetis C, Zurita AJ, Navin NE. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol 21(1):162, 2020. e-Pub 2020. PMID: 32631448.
5. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
6. Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience. BJU Int 118(2):264-71, 2016. e-Pub 2015. PMID: 26573089.
7. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 117(5):761-5, 2016. e-Pub 2015. PMID: 26032863.
8. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-62, 2016. e-Pub 2015. PMID: 26343003.
9. Maiti A, Brown RE, Corn PG, Murthy R, Ganeshan DM, Tsimberidou AM, Subbiah V. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clin Genitourin Cancer 14(2):e187-93, 2016. e-Pub 2015. PMID: 26684814.
10. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34(12):1402-18, 2016. e-Pub 2016. PMID: 26903579.
11. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 2016. e-Pub 2015. PMID: 26546618.
12. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22(1):107-21, 2016. e-Pub 2015. PMID: 26272062.
13. Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 7:11674, 2016. e-Pub 2016. PMID: 27241286.
14. Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res 75(22):4949-59, 2015. e-Pub 2015. PMID: 26530902.
15. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2014. PMID: 25465491.
16. Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 34(22):2815-22, 2015. e-Pub 2014. PMID: 25132269.
17. Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol 67(2):310-8, 2015. e-Pub 2014. PMID: 24631409.
18. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 2015. e-Pub 2014. PMID: 25155428.
19. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med 6(252):252ra122, 2014. PMID: 25186177.
20. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI.. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of Clinical Oncology 32(30):3391-9. e-Pub 2014. PMID: 25225437.
21. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clin Genitourin Cancer. e-Pub 2014. PMID: 25087088.
22. Hussain M, Corn PG, Michaelson MD, Hammers H, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ. Phase II Study of Single Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. Clin Cancer Res. e-Pub 2014. PMID: 24965748.
23. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 2014. e-Pub 2014. PMID: 24847116.
24. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. e-Pub 2014. PMID: 24522479.
25. Corn PG, Wang F, McKeehan WL, Navone N. Targeting Fibroblast Growth Factor Pathways in Prostate Cancer. Clin Cancer Res 19(21):5856, 2013. e-Pub 2013. PMID: 24052019.
26. Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes AML cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. e-Pub 2013. PMID: 24144307.
27. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 2013. e-Pub 2013. PMID: 23810246.
28. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules. J Urol. e-Pub 2013. PMID: 24018239.
29. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes. BJU Int. e-Pub 2013. PMID: 24053120.
30. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. e-Pub 2013. PMID: 23752182.
31. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res. e-Pub 2013. PMID: 23649003.
32. Abouharb S, Corn PG. Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer. Curr Oncol Rep. e-Pub 2013. PMID: 23568599.
33. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, Depetrillo TA, Mathew P. Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study. Int J Radiat Oncol Biol Phys. e-Pub 2013. PMID: 23541810.
34. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 31(4):412-9, 2013. e-Pub 2012. PMID: 23169517.
35. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys. e-Pub 2012. PMID: 23102837.
36. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 107(9):1547-53, 2012. e-Pub 2012. PMID: 23033003.
37. Corn PG. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Management and Research 4:183-193, 2012. e-Pub 2012.
38. Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 2012. PMID: 22168167.
39. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. e-Pub 2011. PMID: 22035268.
40. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. J Natl Cancer Inst. e-Pub 2011. PMID: 21917607.
41. Corn PG. Using methylation analysis to assess tumor heterogeneity in familial breast cancer. Cancer Biol Ther 11(12). e-Pub 2011. PMID: 21577053.
42. Tsao CC, Corn PG. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines. Cancer Biol Ther 10(12). e-Pub 2010. PMID: 20953142.
43. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. e-Pub 2010. PMID: 21115604.
44. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Cin PD, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. e-Pub 2010. PMID: 20665500.
45. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Dovepress: Cancer Management and Research 2010:2:11-122, 2010. e-Pub 2010.
46. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 34(3):364-72, 2010. e-Pub 2009. PMID: 19732952.
47. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma. Cancer 116(1):57-65, 2010. PMID: 19862815.
48. Corn PG. Methylation marks the path for biomarker development in breast cancer research. Cancer Biol Ther 8(23):2260-62, 2009. e-Pub 2009. PMID: 19901521.
49. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 8(22):2151-7, 2009. e-Pub 2009. PMID: 19855158.
50. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 2009. e-Pub 2009. PMID: 19636008.
51. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn PG. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8(3):245-52, 2009. e-Pub 2009. PMID: 19106640.
52. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7(10):1619-27, 2008. e-Pub 2008. PMID: 19018165.
53. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvulo V, Corn P, Hanoaka N, Konopleva M, Andreef M, Nakakuma H. The dual P13 kinase/mTOR inhibotor P1-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22(9):1728-36, 2008. PMID: 18548093.
54. Gardner LB, Corn PG. Hypoxic regulation of mRNA expression. Cell Cycle 7(13):1916-24, 2008. e-Pub 2008. PMID: 18604161.
55. Corn PG,. Genome-wide profilling of methylated promoters in pancreatic adenocarcinoma:defining the pancreatic cancer epigenome. Cancer Biol Ther 7(7):1157-9, 2008. e-Pub 2008. PMID: 18698160.
56. Corn PG. Hypoxic regulation of miR-210: Shrinking targets expand HIF-1's influence. Cancer Biol Ther 7(2):265-7, 2008. e-Pub 2008. PMID: 18347426.
57. Corn PG, El-Deiry WS. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther 6(12):1858-66, 2007. e-Pub 2007. PMID: 18087215.
58. Corn PG. Role of the Ubiquitin-proteasome system in Renal Cell Carcinoma. BMC Biochem 8 Suppl(1:S4):S4, 2007. PMID: 18047741.
59. Corn PG. Reactivation of p53 function with a demethylating agent. Cancer Biol Ther 5(9):1161-2, 2006. PMID: 17012838.
60. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El-Deiry WS. Mx1 is induced by hypoxia in a HIF-1 dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 4(11):1285-94, 2005. e-Pub 2005. PMID: 16319523.
61. Corn PG, McDonald ER, Herman JG, El-Deiry WS. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet 3(3):229-37, 2003. e-Pub 2003. PMID: 14556007.
62. Rikhof B, Corn PG, El-Deiry WS. Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther 2(6):707-12, 2003. PMID: 14688482.
63. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 24(1):47-51, 2003. PMID: 12538348.
64. Corn PG, El-Deiry WS. Derangement of growth and differentiation control in oncogenesis. Bioessays 24(1):83-90, 2002. PMID: 11782953.
65. Corn PG, Heath EI, Heitmiller R, Fogt F, Forastiere AA, Herman JG, Wu TT. Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 7(9):2765-9, 2001. PMID: 11555590.
66. Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett JR, Tazelaar HD, Trastek V, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso NE, Harris CC. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 61(4):5636-43, 2001. PMID: 11454718.
67. Corn PG, Esteller M, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 61(8):3225-9, 2001. PMID: 11309270.
68. Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins DN, Capella G, Peinado MA, Matias-Guiu X, Prat J, Baylin SB, Herman JG. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61(7):2816-21, 2001. PMID: 11306450.
69. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-cadherin expression is silenced by 5'CpG island methylation in acute leukemia. Clin Cancer Res 6(11):4243-8, 2000. PMID: 11106238.
70. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA, Herman JG. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 19(1):164-8, 2000. PMID: 10644993.
71. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5'CpG island methylation. Cancer Res 59(14):3352-6, 1999. PMID: 10416592.
72. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59(4):798-802, 1999. PMID: 10029065.
73. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58(20):4515-8, 1998. PMID: 9788592.
74. Corn PG, Anders J, Takala AK, Käyhty H, Hoiseth SK. Genes involved in haemophilus influenzae type b capsule expression are frequently amplified. J Infect Dis 167(2):356-64, 1993. PMID: 8421169.
75. Hoiseth SK, Corn PG, Anders J. Amplification status of capsule genes in Haemophilus influenzae type b clinical isolates. J Infect Dis 165 Suppl 1:S114, 1992. PMID: 1588141.
76. Corn PG, Mulroney SE, Haramati A. Restoration of a phosphaturic response to parathyroid hormone in the immature rat. Pediatr Res 26(1):54-7, 1989. PMID: 2771508.

Abstracts

1. Corn PG, Zurita AJ, Subudhi SK, Tu SM, Aparicio A, Araujo JC, Kim J, Wang J, Efstathiou E, Pagliaro LC, Logothetis CJ. Cabozantinib plus Androgen Deprivation Therapy in Patients with Androgen-Dependent Metastatic Prostate Cancer. ASCO - American Society of Clinical Oncology, 2017.
2. Basourakos SP, Li L, Aparacio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Bentham Science. e-Pub 2017.
3. Corn PG, Tu SH, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A.. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(suppl; abstr 5010), 2015.
4. Aparicio A, Shen L, Ning Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn PG, Thompson TC, Broom BM, Baggerly KA, Logothetis C, Maity SN,. Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). J Clin Oncol 33(suppl; abstr 5055), 2015.
5. Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, DeBono JS, Schwartz LH, Beer TM, Kelly WK, Hussain M, Sartor AO, Kantoff PW, Armstrong AJ.. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). J Clin Oncol 33(suppl; abstr 5000), 2015.
6. Campbell MT, Shah AY, Hashemi N, Nautiyal KD, Corn PG, Pagliaro LC, Jonasch E, Tannir NM.. Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol 33(suppl 7; abstr 510), 2015.
7. Campbell MT, Shah AY, Nautiyal KD, Hashemi N, Corn PG, Pagliaro LC, Jonasch E, Tannir NM.. Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma (mRCC). J Clin Oncol 33(suppl 7; abstr 472). e-Pub 2015.
8. Shah AY, Campbell MT, Nautiyal KD, Hashemi N, Matin SF, Vapriciyan AA, Rhines L, Moon B, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CG, Jonasch E, Tannir NM.. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol 33(suppl 7; abstr 504), 2015.
9. Bilen MH, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM,.. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clini Oncol 32(suppl; abstr e16046), 2014.
10. Corn PG, Tu SM, Zurita AJ, Araujo JC, Pagliaro LC, Logothetis C, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32(suppl 4; abstr 148), 2014.
11. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. J Clin Oncol 32(suppl 4; abstr 527), 2014.
12. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. J Clin Oncol 32(suppl 4; abstr 528), 2014.
13. Jardim DL, De Melo Galiato D, Falchook GS, Wheler JJ, Zinner R, Janku F, Subbiah V, Phia-Paul. c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. J Clin Oncol 32(suppl 4; abstr 407), 2014.
14. Atkinson BJ, Kalra S, Wang X, Bathala T, Perpich J, Corn PG, Tannir NM, Jonasch E. Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single-center experience. J Clin Oncol, 2013.
15. Jonasch E, Corn PG, Pagliaro LC, Lara P, Wang X, Do KA, Garza R, Bird S, Drabick JJ, Marcott V, Quinn D, Doyle A, Tannir NM. Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients. J Clin Oncol, 2013.
16. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do KA, Wang X, Marcott VD, Matin SF, Tannir NM.. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol, 2013.
17. Cauley DH, Atkinson BJ, Chaan NS, Millikan RE, Xiao L, Corn PG, Jonasch E, Tannir NM. mTOR inhibitor-associated noninfectious pneumonitis in patients with metastatic renal cell cancer: A single-center experience. J Clin Oncol, 2013.
18. Dayyani F, Nogueras-Gonzalez GM, Slack R, Millikan RE, Zurita AJ, Araujo JC, Gallick GE, Logothetis C, Corn PG. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). J Clin Oncol, 2013.
19. Scher HI, Smith MR, Sweeney C, Corn PG, Logothetis C, Vogelzang NJ, Smith DC, Hussain M, George DJ, De Bono JS, Higano CS, Small EJ, Goldin J, Brown MS, Aftab DT, Noursalehi M, Weitzman A, Basch EM. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. J Clin Oncol, 2013.
20. Hussain M, Corn PG, Michaelson D, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, MacLean D, Lee S, Lin MH, Zhu Y, Shi H, Mortimer P, George DJ. Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol, 2013.
21. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn PG, Charnsangavej C, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updated results. J Clin Oncol, 2013.
22. Corn PG, Varkaris A, Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol, 2013.
23. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated penumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol, 2012.
24. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experieince. J Clin Oncol, 2012.
25. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol, 2012.
26. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. J Clin Oncol, 2012.
27. George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Mortimer P, Hussain M. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study. J Clin Oncol, 2012.
28. Smith MR, Sweeney C, Rathkopf DE, Scher HI, Logothetis C, George DJ, Higano CS, Yu EY, Harzstark AL, Small EJ, Sartor AO, Gordon MS, Vogelzang NJ, Smith DC, Hussain M, De Bono JS, Haas NB, Scheffold C, Lee Y, Corn PG. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). J Clin Oncol, 2012.
29. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol, 2011.
30. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol, 2011.
31. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol, 2011.
32. Bilen MA, Liu D, Mathew P, Pagliaro LC, Logothetis C, Araujo JC, Aparicio A, Corn PG, Hajdenberg J, Dakhil SR, Tu S. A randomized phase II study of bone-targeted therapy in advanced androgen-dependent prostate cancer. J Clin Oncol, 2011.
33. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol, 2011.
34. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzrock R, Lara P, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol, 2011.
35. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol, 2010.
36. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol, 2010.
37. Tsao CC, Corn PG. Nutlin-3a induces growth arrest in kidney cancer cell lines in a p53-dependent manner. AACR - 100th Annual Meeting, 2009.
38. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with systemic therapy without cytoreductive nephrectomy. J Clin Oncol, 2009.
39. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol, 2009.
40. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E.. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa:Clinical results and biomarker analysis. ASCO Proceedings 5093, 2008.
41. Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 5104, 2007. e-Pub 2007.
42. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S, Jonasch E. Von Hippel-Lindau gene mutation stuatus is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. Journal of Clinical Oncology 15522, 2007. e-Pub 2007.

Book Chapters

1. Bilen, Mehemet A., Logothetis, Christopher J., Corn, Paul G.. The Management of Prostate Cancer. In: MD Anderson Manual of Medical Oncology. 3rd Edition. McGraw-Hill, 2015.
2. Corn, Paul G, Logothetis, Christopher. The Management of Prostate Cancer. In: The M D Anderson Manual of Medical Oncology. 2nd Edition. McGraw-Hill, 2010.